Drdalebredesen

ReCODE stands for Reversal of Cognitive Decline, and it is the signature methodology Dr. Bredesen developed after decades of neuroscience research. Rather than targeting a single cause of Alzheimer's, it personalises interventions across metabolic, inflammatory, vascular, and toxic factors identified through lab testing. It is the foundation of everything Dr. Bredesen teaches across his books, clinical work, and social media content.

Dr. Bredesen has published case reports and small studies documenting patients who recovered meaningful cognitive function after following his ReCODE protocol, claims he details extensively in his books and online content. Mainstream neurologists have pushed back, noting that large randomised controlled trials are still needed to confirm the findings at scale. The tension between his documented cases and conventional evidence standards is one of the most debated aspects of his work.

The End of Alzheimer's, published in 2017, argues that Alzheimer's disease is not caused by a single mechanism but is instead a metabolic syndrome of the brain driven by dozens of overlapping factors. Dr. Bredesen outlines how identifying and addressing those individual drivers — rather than chasing one drug target — can halt and in some cases reverse cognitive decline. The book brought his research to a wide public audience and remains the primary entry point into his ideas for most readers.

Dr. Bredesen's central argument is that the amyloid plaques associated with Alzheimer's are not the root cause but rather a protective response the brain mounts against multiple threats — including chronic inflammation, insulin resistance, hormonal imbalances, and toxin exposure. He has described Alzheimer's as a condition with at least several distinct subtypes, each requiring a different therapeutic approach. This multi-driver model sets his framework apart from the dominant single-target drug research approach.

KetoFLEX 12/3 is the dietary approach Dr. Bredesen developed as part of his broader ReCODE protocol, combining a mildly ketogenic, heavily plant-rich eating pattern with a minimum 12-hour overnight fast and no food in the 3 hours before bed. The goal is to promote metabolic flexibility and reduce insulin resistance, both of which he connects directly to brain health and dementia risk. He positions it not as a standalone diet trend but as one component of a personalised, clinician-guided plan.

Dr. Bredesen co-founded Apollo Health as the commercial platform through which his ReCODE protocol is delivered to patients at scale, connecting individuals with practitioners trained in his methodology. Users receive personalised guidance based on detailed lab work and health history rather than a one-size-fits-all plan. It represents the direct translation of his published research into an accessible clinical service.

Dr. Bredesen spent decades at major research institutions including UCLA, the Gladstone Institute of Neurological Disease at UCSF, and the Buck Institute for Research on Aging in Novato, California, where he led neurodegeneration research for many years. That lengthy career in academic neuroscience is what he points to when making the case for the scientific grounding behind the ReCODE protocol. His work with Nobel laureate Stanley Prusiner early in his career also shaped his thinking on neurological disease mechanisms.

The mainstream medical community has largely been cautious, with prominent Alzheimer's researchers noting that his most cited results come from small case series rather than the large randomised controlled trials that set the standard for clinical acceptance. Supporters argue that the urgency of the Alzheimer's epidemic justifies applying his protocol while larger trials are conducted, and that the lifestyle components carry minimal risk regardless. The debate around his work is ongoing and is itself a recurring topic in his content.

Beyond The End of Alzheimer's, Dr. Bredesen has written The End of Alzheimer's Program, which focuses on practical implementation of his protocol, and The First Survivors of Alzheimer's, which features first-person accounts from patients who followed his approach. Together the books form a layered resource moving from the science to the application to the lived patient experience. His social media content often bridges all three, making it a companion to the written series.

Dr. Bredesen is most active on YouTube and Instagram, using both to share research explainers, protocol breakdowns, and updates on brain health science. His Instagram engagement runs well above the typical rate for health and science creators, which reflects a highly invested audience tracking his work closely. He posts consistently across both platforms and can be found under the handle @drdalebredesen.